30 January 2024 : Clinical Research
Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo
Edmond Komoni1ABCDEFG, Fisnik Jashari1ACD, Dren Boshnjaku1DF, Blerim Myftiu2BF, Melihate Pushka1BF, Afrim Blyta1A, Rajmonda Nallbani-Komoni
3ACEF*
DOI: 10.12659/MSM.942992
Med Sci Monit 2024; 30:e942992
Table 1 Patients’ clinical and demographical data.
| Variable | n=282 |
|---|---|
| Age, mean (SD) | 37.8 (11.0) |
| Gender (Female), n (%) | 183 (64.9) |
| Smoking, n (%) | 69 (24.4) |
| Hypertension, n (%) | 21 (7.4) |
| Diabetes mellitus, n (%) | 3 (1.1) |
| MS type, n (%) | |
| RR | 202 (71.6) |
| SP | 55 (19.5) |
| PP | 25 (8.9) |
| EDSS, mean (SD) | 3.5 (2.2) |
| Years with MS, mean (SD) | 8.6 (6.8) |
| DMT, n (%) | |
| None | 22 (7.7) |
| Interferons | 206 (75.5) |
| Anti-CD20 | 32 (11.8) |
| Other | 13 (4.8) |
| Years on DMT, mean (SD) | 2.78 (3.1) |
| COVID-19 infection, n (%) | 272 (96.4) |
| Symptoms, n (%) | |
| Asymptomatic | 154 (57.0) |
| Mild | 107 (39.6) |
| Moderate | 6 (2.2) |
| Severe | 5 (1.1) |
| Los of smell, n (%) | 53 (42.7) |
| Los of taste, n (%) | 56 (45.1) |
| Lung infiltration, n (%) | 11 (15.5) |
| DMT – disease-modifying therapy; EDSS – Expanded Disability Status Scale; MS – multiple sclerosis. | |